Drug intelligence / Profile preview

COVID-19 vaccine (Vero cell), inactivated

Development stage
Phase 2
Lead developer
Sinopharm
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

COVID-19 vaccine (Vero cell), inactivated refers to a class of whole-virion inactivated vaccines developed to prevent COVID-19. These vaccines are produced by growing SARS-CoV-2 in Vero cell cultures, followed by chemical inactivation (typically with beta-propiolactone) to render the virus non-infectious while preserving its antigenic structure. The resulting inactivated virus is purified and usually formulated with an aluminum hydroxide adjuvant. Prominent examples include Sinovac's CoronaVac and Sinopharm's BBIBP-CorV (COVILO). By presenting the entire inactivated virus to the immune system, these vaccines elicit a broad immune response against multiple viral proteins, including the spike (S), nucleocapsid (N), envelope (E), and membrane (M) proteins, leading to the production of neutralizing antibodies and activation of T-cell mediated immunity.

Brand names
CoronaVacCOVILOHayat-VaxKCONVAC
Other names
Inactivated SARS-CoV-2 vaccine (Vero cell)SARS-CoV-2 vaccine (Vero cell), inactivatedInactivated COVID-19 vaccineWhole-virion inactivated SARS-CoV-2 vaccine
02

Targets

E (Tick-borne encephalitis virus envelope protein)M protein (SARS-CoV-2 membrane protein)N (Nucleocapsid protein)SARS-CoV-2 spike

Beyond the preview

Go deeper on COVID-19 vaccine (Vero cell), inactivated.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on COVID-19 vaccine (Vero cell), inactivated.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call